NRG1 fusion positive tumors

Zenocutuzumab receives Breakthrough Designation from the FDA for NRG1+ Pancreatic Cancer

Source – Merus On July 5, The FDA has granted breakthrough therapy designation to zenocutuzumab (MCLA-128) as a treatment for ...